^
    Back
    Association details:
    Biomarker:RB1 deletion
    Cancer:Mantle Cell Lymphoma
    Drug:Ibrance (palbociclib) (CDK4/6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2021
    Title:

    Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma

    Published date:
    11/04/2021
    Excerpt:
    We confirmed on MCL cells, that RB1 knockdown causes resistance to palbociclib and represents a negative predictive marker.
    DOI:
    10.1182/blood-2021-150517